Skip to main content

Market Overview

Merck CEO: Using Keytruda Could Extend Patient's Life By 13 Months On Average


Speaking to Fox Business Network, Merck & Co., Inc. (NYSE: MRK)'s CEO Kenneth Frazier discussed the company's Keytruda drug that is used to treat patients suffering from lung cancer.

Frazier, citing recent data from studies, said that using Keytruda could extend the life of a patient by approximately 13 months on average.

"This is a new category of drugs that stimulates the body's immune system," the executive said. "We know that it will reduce the risk of death by 30-40 percent for people who had failed on standard chemo-therapy."

Separately, Frazier commented on the recent wave of M&A in the sector, particularly tax inversion deals. He said that U.S.-based pharmaceutical companies are at a "structural disadvantage" in terms of global competition for IP assets, talent and capital.


Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Cancer Treatment Fox Business News Kenneth Frazier KeytrudaNews Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at